Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast will be available in the Investors section of Maze Therapeutics' website at www.mazetx.com, and the presentation will be archived for 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – MAZE
In the Jan 5 session, MAZE declined 2.87%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Negative | -3.5% | Higher R&D and G&A drove net loss despite strong cash runway and pipeline data. |
| Nov 06 | Clinical data update | Positive | -2.1% | Additional MZE782 and MZE829 data at ASN Kidney Week signaled advancing kidney programs. |
| Nov 04 | Investor conferences | Neutral | -2.5% | Management participation in multiple investor conferences to highlight strategy and programs. |
| Oct 06 | Chairman appointment | Positive | +1.5% | Appointment of experienced chairman alongside recap of financing and 2026 clinical milestones. |
| Sep 11 | Private placement | Positive | +54.8% | Oversubscribed $150.0 million private placement at a premium to fund key programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often coincided with either modest declines after scientific or corporate updates, while financing and capital-related announcements like the oversubscribed $150.0 million private placement saw a strong positive reaction.
Over the last several months, Maze highlighted strengthening finances and pipeline progress. Q3 2025 results showed a net loss of $96.6 million year‑to‑date but cash of $383.9 million, supported by an IPO and an oversubscribed $150.0 million private placement. Clinical updates for MZE782 and MZE829, plus multiple conference presentations, underscored focus on APOL1‑mediated kidney disease and PKU/CKD. Today’s J.P. Morgan conference participation fits the pattern of active investor and scientific engagement following 2025 financing and leadership changes.
Key Terms
small molecule medical
precision medicines medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 30 days following the presentation.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.
IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com
Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com
